Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedIntroduced a Locations section listing study sites in California, Connecticut, Florida, New York, Texas, Utah, New South Wales, and Ontario, reorganizing location details under a single header. The page revision is updated to v3.3.3.SummaryDifference1%

- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now shows a new revision label 'Revision: v3.3.2', replacing the previous 'v3.3.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedPublications section now notes that articles are auto-filled from PubMed, and the page revision is updated to v3.3.1 (from v3.2.0).SummaryDifference0.1%

- Check56 days agoChange DetectedThe notice about a lapse in government funding and NIH operating status at the top of the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedNo significant content changes detected between the old and new page; core study details, eligibility criteria, outcomes, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check99 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference5%

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.